M6A-Induced LncRNA MEG3 Suppresses the Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cell Through MiR-544b/BTG2 Signaling

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Jun 24

PMID 34163177

Citations 34

Authors

Jian Wu

Runhua Pang

Minan Li

Bin Chen

Junhai Huang

Yaqing Zhu

Affiliations

Soon will be listed here.

Abstract

Objective: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Long non-coding RNA plays an important role in the development of HCC. This study analyzed the impact of MEG3 on malignant behavior of HCC and explored its possible molecular mechanism.

Methods: Expression of MEG3 in HCC tissues and cell lines was measured by qRT-PCR. Transfection efficiency of MEG3 was verified by qRT-PCR. Cell proliferation, transwell migration, invasion and cell cloning assays were used to detect the effect of MEG3 on the proliferation, migration and invasion ability of HCC cells. The bioinformatics analysis was applied to predict the binding between miR-544b and MEG3 as well as BTG2. Luciferase reporter assay was performed to verify their interaction. Finally, the m6A modification of MEG3 by METTL3 was identified through RIP experiments.

Results: MEG3 was lowly expressed in HCC tissues and cells. Overexpression of MEG3 inhibits the proliferation, migration and invasion of HCC cells. MiR-544b can be sponged by MEG3, and overexpression of miR-544b reverses the anti-cancer effect of MEG3. We further confirmed that BTG2 gene is the target gene of miR-544b. Epigenetic studies have shown that METTL3-mediated N-methyladenosine modification led to MEG3 downregulation.

Conclusion: In HCC, MEG3 and BTG2 are lowly expressed while miR-544b is highly expressed. MEG3 regulates the expression of BTG2 through miR-544b, thus affecting the malignant behavior of HCC. METTL3 regulates the m6A modification of MEG3 and its expression. This study clarified the role of MEG3/miR-544b/BTG2 axis in HCC and also provided new targets for HCC research.

Citing Articles

Genome-wide profiling of N6-methyladenosine-modified pseudogene-derived long noncoding RNAs reveals the tumour-promoting and innate immune-restraining function of RPS15AP12 in ovarian cancer.

Xu J, Ren Y, Lu J, Qin F, Yang D, Tang C Clin Transl Med. 2025; 15(3):e70249.

PMID: 40000433 PMC: 11859666. DOI: 10.1002/ctm2.70249.

N6-methyladenosine-modified long non-coding RNA promotes stemness and sorafenib resistance in hepatocellular carcinoma by upregulating SHOX2 expression.

Yu Y, Lu X, Mu J, Meng J, Sun J, Chen H World J Gastroenterol. 2024; 30(48):5174-5190.

PMID: 39735272 PMC: 11612700. DOI: 10.3748/wjg.v30.i48.5174.

Overview of the interplay between m6A methylation modification and non-coding RNA and their impact on tumor cells.

Dou Z, Ma X, Piao M, Wang J, Li J Transl Cancer Res. 2024; 13(6):3106-3125.

PMID: 38988908 PMC: 11231769. DOI: 10.21037/tcr-23-2401.

RNA modifications in the progression of liver diseases: from fatty liver to cancer.

Li S, Mehal W, Ouyang X Sci China Life Sci. 2024; 67(10):2105-2119.

PMID: 38809498 PMC: 11545962. DOI: 10.1007/s11427-023-2494-x.

N6-Methyladenosine in Cell-Fate Determination of BMSCs: From Mechanism to Applications.

Zhang Q, Li J, Wang C, Li Z, Luo P, Gao F Research (Wash D C). 2024; 7:0340.

PMID: 38665846 PMC: 11045264. DOI: 10.34133/research.0340.

References

Kwon Y, Jun J, Shin S, Cho J, Suh S . Curcumin decreases cell proliferation rates through BTG2-mediated cyclin D1 down-regulation in U937 cells. Int J Oncol. 2005; 26(6):1597-603. View

Mendell J . Targeting a Long Noncoding RNA in Breast Cancer. N Engl J Med. 2016; 374(23):2287-9. DOI: 10.1056/NEJMcibr1603785. View

Tang X, Feng D, Li M, Zhou J, Li X, Zhao D . Transcriptomic Analysis of mRNA-lncRNA-miRNA Interactions in Hepatocellular Carcinoma. Sci Rep. 2019; 9(1):16096. PMC: 6834564. DOI: 10.1038/s41598-019-52559-x. View

Wang L, Chen Z, An L, Wang Y, Zhang Z, Guo Y . Analysis of Long Non-Coding RNA Expression Profiles in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2016; 38(6):2389-400. DOI: 10.1159/000445591. View

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

Duriez C, Falette N, Audoynaud C, Moyret-Lalle C, Bensaad K, Courtois S . The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene. 2002; 282(1-2):207-14. DOI: 10.1016/s0378-1119(01)00825-3. View

Wang L, Guo Z, Zhang R, Xin B, Chen R, Zhao J . Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis. 2013; 34(8):1773-81. DOI: 10.1093/carcin/bgt139. View

Yanaka Y, Muramatsu T, Uetake H, Kozaki K, Inazawa J . miR-544a induces epithelial-mesenchymal transition through the activation of WNT signaling pathway in gastric cancer. Carcinogenesis. 2015; 36(11):1363-71. DOI: 10.1093/carcin/bgv106. View

Pan C, Xiang L, Pan Z, Wang X, Li J, ZhuGe L . MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer. Cancer Cell Int. 2018; 18:52. PMC: 5883289. DOI: 10.1186/s12935-018-0542-y. View

10.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

11.

Ma H, Huang C, Huang Q, Li G, Li J, Huang B . Circular RNA circ_0014717 Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating miR-668-3p/BTG2 Axis. Front Oncol. 2021; 10:592884. PMC: 7883829. DOI: 10.3389/fonc.2020.592884. View

12.

Goldberg D, Valderrama A, Kamalakar R, Sansgiry S, Babajanyan S, Lewis J . Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance. J Clin Gastroenterol. 2015; 50(3):258-65. DOI: 10.1097/MCG.0000000000000411. View

13.

Liz J, Esteller M . lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2015; 1859(1):169-76. DOI: 10.1016/j.bbagrm.2015.06.015. View

14.

Amort T, Rieder D, Wille A, Khokhlova-Cubberley D, Riml C, Trixl L . Distinct 5-methylcytosine profiles in poly(A) RNA from mouse embryonic stem cells and brain. Genome Biol. 2017; 18(1):1. PMC: 5225599. DOI: 10.1186/s13059-016-1139-1. View

15.

Hong J, Ryu M, Lim I . Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death. J Biol Chem. 2005; 280(22):21256-63. DOI: 10.1074/jbc.M500318200. View

16.

Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y . CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010; 38(16):5366-83. PMC: 2938198. DOI: 10.1093/nar/gkq285. View

17.

Terra R, Luo H, Qiao X, Wu J . Tissue-specific expression of B-cell translocation gene 2 (BTG2) and its function in T-cell immune responses in a transgenic mouse model. Int Immunol. 2008; 20(3):317-26. DOI: 10.1093/intimm/dxm152. View

18.

Zhu Z, Wang S, Zhu J, Yang Q, Dong H, Huang J . MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer. Biol Chem. 2016; 397(10):1087-95. DOI: 10.1515/hsz-2016-0104. View

19.

Ren S, Li G, Liu C, Cai T, Su Z, Wei M . Next generation deep sequencing identified a novel lncRNA n375709 associated with paclitaxel resistance in nasopharyngeal carcinoma. Oncol Rep. 2016; 36(4):1861-7. PMC: 5024742. DOI: 10.3892/or.2016.4981. View

20.

Liu J, Sun G, Pan S, Qin M, Ouyang R, Li Z . The Cancer Genome Atlas (TCGA) based mA methylation-related genes predict prognosis in hepatocellular carcinoma. Bioengineered. 2020; 11(1):759-768. PMC: 8291839. DOI: 10.1080/21655979.2020.1787764. View